AbbVie, Parkinson and Phase III
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.
AbbVie announces positive phase 3 results for Parkinson’s drug
These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also met its primary endpoint ​ earlier this year. The final trial, TEMPO-2 is testing flexible dose tavapadon, also as a monotherapy, and is expected to read out before the end of the year.
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three years.
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-1 study which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson’s disease (PD).
AbbVie Parkinson’s drug helps improve symptoms in late-stage study
AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study. In the Phase 3 trial,
AbbVie Parkinson's disease therapy hits main goal in late-stage trial
AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease. Read more here.
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company ...
Final Trades: Meta, Accenture, Abbvie and Disney
Maggie Smith, acting legend of 'Harry Potter' and 'Downton Abbey' fame, dies at 89 Aerial footage shows extensive Helene ...
Becker's Hospital Review1h
AbbVie drug shows promise in treating Parkinson's: 3 notes
The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson's disease. Patients receiving the drug at doses of 5 ...
AbbVie Inc. stock rises Thursday, still underperforms market
Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA ...
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug ...
FierceBiotech1d
AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial
AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in ...
Bristol Myers Squibb Vs. AbbVie Stock
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
hrexecutive4d
Creating culture from the ground up: How AbbVie did it
After spinning off from Abbott Labs in 2013, biopharmaceutical giant AbbVie had to establish its own culture. Here's how the ...
Zacks.com on MSN8h
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...